Cargando…
Prospects for clinical use of reprogrammed cells for autologous treatment of macular degeneration
Since the discovery of induced pluripotent stem cells (iPSC) in 2006, the symptoms of many human diseases have been reversed in animal models with iPSC therapy, setting the stage for future clinical development. From the animal data it is clear that iPSC are rapidly becoming the lead cell type for c...
Autores principales: | Alvarez Palomo, Ana Belen, McLenachan, Samuel, Chen, Fred K, Da Cruz, Lyndon, Dilley, Rodney J, Requena, Jordi, Lucas, Michaela, Lucas, Andrew, Drukker, Micha, Edel, Michael J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4432516/ https://www.ncbi.nlm.nih.gov/pubmed/25984235 http://dx.doi.org/10.1186/s13069-015-0026-9 |
Ejemplares similares
-
The Power and the Promise of Cell Reprogramming: Personalized Autologous Body Organ and Cell Transplantation
por: Alvarez Palomo, Ana Belen, et al.
Publicado: (2014) -
mRNA Transfection of Mouse and Human Neural Stem Cell Cultures
por: McLenachan, Samuel, et al.
Publicado: (2013) -
iPS Cells for Modelling and Treatment of Retinal Diseases
por: Chen, Fred K., et al.
Publicado: (2014) -
Bioengineered Bruch's-like extracellular matrix promotes retinal pigment epithelial differentiation
por: McLenachan, Samuel, et al.
Publicado: (2017) -
New developments in age-related macular degeneration
por: da Cruz, Lyndon
Publicado: (2008)